Revolution Medicines Inc. (RVMD)
There's a Revolution in Cancer. But Can Big Pharma Afford It?
Revolution Medicines' stock has surged on the promise of a pancreatic-cancer drug. With any deal to buy the firm looking unlikely, investors should be prepared for the long haul.
RVMD Stock Rallies 41% on Positive Phase III Pancreatic Cancer Data
Revolution Medicines jumps 41% as phase III data show daraxonrasib boosts survival in metastatic PDAC, paving the way for global regulatory filings.
How This Biotech Stock Skirted Today's Selloff
Revolution Medicines Inc (NASDAQ:RVMD) stock is brushing off the broad market selloff this morning, last seen up 35.5% to trade at $131.35, and earlier hitting a record high of $135.81.
Revolution Medicines surges 38% as pancreatic cancer drug shows breakthrough
Shares of Revolution Medicines surged sharply on Monday after the company reported positive results from a late-stage trial of its experimental pancreatic cancer drug, raising hopes for a potential breakthrough in one of the deadliest forms of the disease. The stock climbed 38% after the opening bell, extending gains to 69% since the start of the year.
Revolution Medicines' experimental cancer pill helps improve survival in late-stage study
Revolution Medicines' experimental oral drug helped patients with pancreatic cancer live longer and showed an improvement in survival without worsening of the disease in a keenly anticipated late-stage trial.
Revolution Medicines' potential breakthrough pancreatic cancer drug succeeds in late-stage trial
Revolution Medicines says its pancreatic cancer drug daraxonrasib succeeded in a Phase 3 trial. RevMed said its drug almost doubled the typical length of survival and slashed the risk of death by 60% versus chemotherapy.
Former Sen. Ben Sasse shines the spotlight on a possible breakthrough for pancreatic cancer
Revolution Medicines expects to soon report results from a Phase 3 trial of its daily pill daraxonrasib for pancreatic cancer. Former Republican Sen.
Revolution Medicines (RVMD) Down 8.8% Since Last Earnings Report: Can It Rebound?
Revolution Medicines (RVMD) reported earnings 30 days ago. What's next for the stock?
General Atlantic L.P. Acquires New Position in Revolution Medicines, Inc. $RVMD
General Atlantic L.P. acquired a new stake in Revolution Medicines, Inc. (NASDAQ: RVMD) during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 2,474,428 shares of the company's stock, valued at approximately $115,556,000. Revolution Medicines comprises about 3.5% of General Atlantic L.P.'s investment portfolio,
Revolution Medicines, Inc. (RVMD) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Revolution Medicines, Inc. (RVMD) Presents at TD Cowen 46th Annual Health Care Conference Transcript
RVMD Reports Wider-Than-Expected Q4 Loss, Issues 2026 Expense View
Revolution Medicines posts a wider-than-expected Q4 loss and sees 2026 operating expenses of $1.6B-$1.7B as it advances late-stage RAS pipeline studies.
Revolution Medicines, Inc. (RVMD) Q4 2025 Earnings Call Transcript
Revolution Medicines, Inc. (RVMD) Q4 2025 Earnings Call Transcript
